Home » Newsletters » BioWorld Science

BioWorld Science

March 3, 2003

View Archived Issues

4SC and Boehringer Ingelheim sign drug discovery agreement

New series of antifungal azoles in early development at Aventis

BioTie researchers present new inhibitors of VAP-1 SSAO

New inhibitors of glyceraldehyde-3-phosphate dehydrogenase and their use in cancer

Ortho-McNeil patent covers antiepileptic topiramate salts

Inhibitors of aP2 and their use in diabetes and lipid disorders claimed by BMS

Exelixis and Protein Design Labs' cancer antibody research collaboration progresses

Albany Molecular Research provides chemistry expertise to Affinium

Progress on several fronts at Amersham

Efficacy reported for G-3139-containing chemotherapy in refractory/relapsed acute leukemia

AGI-1067 equally effective and safer than probucol after PCI

Novel anti-HCV NS3 protease agents presented by Vertex

Novel NK1 antagonists and their use covered by Solvay patent

New tetracyclines discovered by Paratek scientists

FDA approves Oxytrol for overactive bladder

Chiron plans U.S.-based phase III trial for Menjugate

Medarex and Ferric collaborate on therapeutic antibody development

SkyePharma achieves proof of principle for Biosphere technology

Microscience's oral typhoid vaccine is safe and immunogenic

Emisphere reports phase IIa data for oral calcitonin

Shire licenses MethyPatch from Noven

P2Y2 agonists and their potential in vaginal dryness in postmenopausal women

Variations in the efficacy of TNP-470 according to the time of day administered

Inhibitor of NFkB activation suppresses growth of hormone-refractory prostate cancer

Anxiolytic-like effects without sedation or ataxia observed for DMP-696 in rats

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...